Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News SeaStar Medical Holding Corp ICU

Healthcare Medical Devices
SeaStar Medical Holding Corporation is a commercial-stage medical technology company. The Company is focused on developing extracorporeal therapies to reduce the consequences of hyperinflammation on vital organs. The Company's technologies rely on science to provide life-saving solutions to critically ill patients. The Company develops and commercializes cell-directed extracorporeal therapies... see more

Recent & Breaking News (NDAQ:ICU)

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU

PR Newswire April 4, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU

Accesswire April 2, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU

PR Newswire March 28, 2024

SeaStar Medical to Restate Financials, Sets Business Update Call for April 17

GlobeNewswire March 27, 2024

SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients

GlobeNewswire March 12, 2024

SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024

GlobeNewswire March 11, 2024

Manuscript Discussing the Benefit of SeaStar Medical's Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure

GlobeNewswire February 27, 2024

Nuwellis' Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune(TM)

GlobeNewswire February 22, 2024

FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical's Selective Cytopheretic Device for Pediatric Acute Kidney Injury

GlobeNewswire February 22, 2024

SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology

GlobeNewswire February 1, 2024

SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market

GlobeNewswire January 26, 2024

SeaStar Medical Appoints David A. Green as Chief Financial Officer

GlobeNewswire January 11, 2024

SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications

GlobeNewswire January 9, 2024

SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

GlobeNewswire December 28, 2023

SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts

GlobeNewswire December 13, 2023

SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update

GlobeNewswire November 14, 2023

Nuwellis' Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device

GlobeNewswire October 31, 2023

FDA Issues Approvable Letter for SeaStar Medical's Selective Cytopheretic Device for Pediatric Patients

GlobeNewswire October 30, 2023

FDA Grants SeaStar Medical's Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome

GlobeNewswire October 18, 2023

SeaStar Medical to Present at the Dawson James Small Cap Growth Conference on October 12, 2023

GlobeNewswire October 5, 2023